
    
      The study will be carried out at Ain Shams University Hospitals. Patients with ACS who meet
      the eligibility criteria and consent to participate in the study will be randomly allocated
      to either the intervention group or the control group.

      All participants will receive the standard pharmacologic treatment for ACS according to the
      applied guidelines offered by the facility. In addition, patients in the intervention group
      will receive Pentoxifylline tablets 400mg orally three times daily.

      Patient follow-up will be scheduled every 2 weeks for each patient to check the tolerability,
      the development of side effects, any medication change and medication adherence. Physical
      examination at each visit will be done by physician in attendance for all patients in both
      groups.

      A blood sample will be taken at baseline and at the end of the study after 2 months. for
      measurement of basic laboratory parameters (Complete Blood Count, Liver Function Tests,
      Kidney Function Tests ,..etc), the level of Soluble Vascular Cell Adhesion Molecule-1
      (sVCAM-1) as a marker for endothelial dysfunction, the level of Malondialdehyde (MDA) as a
      marker for oxidative stress.
    
  